Skip to main content
. 2017 Oct 31;12(10):e0186898. doi: 10.1371/journal.pone.0186898

Table 3. Recipient, donor and other characteristics associated with overall survival of HCV-infected OLT recipients.

Univariate analysis Multivariate analysis*
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Recipient Characteristics
  Gender <0.0001 <0.0001
    Male 15,048 (73.8) Ref. Ref.
    Female 5,337 (26.2) 1.18 (1.11–1.25) 1.17 (1.10–1.25)
  Age 55.0±7.1 1.02 (1.01–1.02) <0.0001 1.02 (1.01–1.02) <0.0001
  Race/Ethnicity <0.0001 <0.0001
    White 14,158 (69.5) Ref. Ref.
    Black 2,512 (12.3) 1.44 (1.34–1.55) 1.31 (1.21–1.42)
    Hispanic 2,862 (14.0) 0.95 (0.88–1.03) 0.89 (0.81–0.97)
    Asian 624 (3.1) 0.92 (0.78–1.08) 0.90 (0.75–1.07)
    Other 229 (1.1) 0.88 (0.67–1.16) 0.88 (0.67–1.17)
  Lab-MELD <0.0001 0.33
    MELD <10 2,660 (13.1) 1.05 (0.95–1.16) 1.02 (0.92–1.14)
    MELD 10–14 4,377 (21.5) Ref. Ref.
    MELD 15–19 4,332 (21.3) 0.95 (0.88–1.04) 1.03 (0.93–1.13)
    MELD 20–24 3,264 (16.0) 1.14 (1.04–1.24) 1.11 (0.98–1.25)
    MELD 25–29 1,976 (9.7) 1.21 (1.09–1.34) 1.19 (1.03–1.39)
    MELD 30–34 1,510 (7.4) 1.31 (1.17–1.46) 1.23 (1.03–1.47)
    MELD 35+ 2,266 (11.1) 1.42 (1.29–1.57) 1.23 (1.00–1.52)
  Allocation MELD <0.0001 0.005
    MELD <10 163 (0.8) 1.17 (0.88–1.55) 1.20 (0.90–1.64)
    MELD 10–14 683 (3.4) Ref. Ref.
    MELD 15–19 2,736 (13.4) 0.84 (0.72–0.98) 0.85 (0.71–1.00)
    MELD 20–24 6,532 (32.0) 1.10 (0.95–1.26) 1.04 (0.87–1.25)
    MELD 25–29 5,150 (25.3) 1.09 (0.95–1.26) 1.02 (0.84–1.23)
    MELD 30–34 2,418 (11.9) 1.21 (1.03–1.41) 1.10 (0.89–1.36)
    MELD 35+ 2,701 (13.3) 1.40 (1.20–1.63) 1.19 (0.93–1.51)
Albumin 3.0±0.7 0.96 (0.92–0.99) 0.02 0.94 (0.90–0.98) 0.007
  Exception case 0.15 0.19
    No 12,142 (59.6) Ref. Ref.
    Yes 8,243 (40.4) 0.96 (0.91–1.02) 1.08 (0.96–1.20)
  ABO blood type 0.63 0.32
    0 9,091 (44.6) Ref. Ref.
    A 7,514 (36.9) 0.99 (0.93–1.05) 1.04 (0.98–1.11)
    AB 1,074 (5.3) 0.94 (0.83–1.06) 1.03 (0.91–1.18)
    B 2,706 (13.3) 0.96 (0.88–1.05) 0.96 (0.88–1.05)
  Encephalopathy 0.02 0.27
    Absent 7,217 (35.4) Ref. Ref.
    Present 13,168 (64.6) 1.07 (1.01–1.13) 1.04 (0.97–1.12)
  Ascites 0.17 0.82
    Absent 4,657 (22.9) Ref. Ref.
    Present 15,728 (77.1) 1.05 (0.98–1.12) 1.01 (0.93–1.10)
  Diabetes <0.0001 <0.0001
    No 15,913 (78.1) Ref. Ref.
    Yes 4,471 (21.9) 1.33 (1.25–1.41) 1.25 (1.17–1.33)
  Dialysis preTX <0.0001 <0.0001
    No 18,464 (90.6) Ref. Ref.
    Yes 1,921 (9.4) 1.52 (1.40–1.66) 1.36 (1.23–1.51)
Donor Characteristics
  Gender <0.001 0.75
    Male 12,291 (60.3) Ref. Ref.
    Female 8,094 (39.7) 1.10 (1.04–1.16) 0.99 (0.94–1.05)
  Age 40.4±15.9 1.02 (1.02–1.02) <0.0001 1.02 (1.02–1.02) <0.0001
  Ethnicity <0.0001 <0.0001
    White 13,567 (66.6) Ref. Ref.
    Black 3,446 (16.9) 0.96 (0.89–1.03) 0.92 (0.85–0.99)
    Hispanic 2,623 (12.9) 1.17 (1.08–1.26) 1.26 (1.15–1.36)
    Asian 473 (2.3) 1.44 (1.23–1.69) 1.39 (1.18–1.64)
    Other 276 (1.4) 1.14 (0.91–1.43) 1.33 (1.05–1.68)
  Diabetes <0.0001 0.03
    No 18,329 (89.9) Ref. Ref.
    Yes 2,056 (10.1) 1.37 (1.26–1.49) 1.10 (1.01–1.20)
  HCV-antibody status 0.69 0.48
    Negative 18,872 (92,6) Ref. Ref.
    Positive 1,472 (7.2) 1.033 (0.93–1.15) 1.06 (0.95–1.19)
    Not reported 41 (0.2) 0.84 (0.48–1.48) 0.85 (0.47–1.55)
Independent Characteristics
    Cold Ischemic Time 7.0±3.4 1.01 (1.01–1.02) <0.01 1.01 (1.00–1.02) <0.01
    Transplant procedure 0.16 0.63
    Whole liver 20,137 (98.8) Ref. Ref.
    Split/partial liver 248 (1.2) 0.83 (0.64–1.08) 1.07 (0.81–1.41)
    Region, N (%)* <0.0001 <0.0001
    1 749 (3.7) Ref. Ref.
    2 2,645 (13.0) 1.04 (0.90–1.21) 1.02 (0.87–1.20)
    3 3,537 (17.4) 0.85 (0.73–0.99) 0.91 (0.77–1.06)
    4 2,121 (10.4) 0.84 (0.72–0.98) 0.89 (0.75–1.05)
    5 3,030 (14.9) 0.82 (0.70–0.96) 0.75 (0.64–0.88)
    6 785 (3.9) 0.70 (0.57–0.85) 0.76 (0.62–0.94)
    7 1,240 (6.1) 0.98 (0.82–1.16) 0.92 (0.77–1.10)
    8 1,322 (6.5) 0.79 (0.66–0.94) 0.87 (0.72–1.04)
    9 1,295 (6.4) 1.12 (0.95–1.33) 0.96 (0.81–1.14)
    10 1,660 (8.1) 0.89 (0.76–1.05) 0.97 (0.82–1.15)
    11 2,001 (9.8) 0.87 (0.74–1.02) 0.95 (0.80–1.13)
    Transplant year 0.05 0.006
    2002 594 (2.9) 0.96 (0.83–1.12) 1.022 (0.870–1.201)
    2003 1,263 (6.2) 0.99 (0.88–1.11) 0.991 (0.874–1.124)
    2004 1,546 (7.6) Ref. Ref.
    2005 1,613 (7.9) 1.01 (0.91–1.14) 0.99 (0.88–1.12)
    2006 1,763 (8.7) 0.98 (0.87–1.10) 0.94 (0.83–1.06)
    2007 1,753 (8.6) 1.00 (0.89–1.12) 1.00 (0.88–1.13)
    2008 1,687 (8.3) 1.16 (1.03–1.30) 1.12 (0.99–1.26)
    2009 1,853 (9.1) 1.06 (0.94–1.19) 0.97 (0.86–1.10)
    2010 1,824 (9.0) 1.00 (0.88–1.14) 0.91 (0.80–1.04)
    2011 1,837 (9.0) 0.91 (0.80–1.04) 0.85 (0.73–0.98)
    2012 1,911 (9.4) 0.92 (0.79–1.07) 0.84 (0.72–0.98)
    2013 1,832 (9.0) 0.91 (0.76–1.09) 0.83 (0.69–1.00)
    2014 909 (4.5) 1.21 (0.83–1.78) 1.08 (0.74–1.57)

Values in column 2 are absolute N (%) or mean±SD

*States and areas in regions of OPTN: 1 Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; 2 Delaware, District of Columbia, Maryland, New Jersey, Pennsylvania, Northern Virginia, West Virginia; 3 Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, Puerto Rico 4 Oklahoma, Texas; 5 Arizona, California, Nevada, New Mexico, Utah; 6 Alaska, Hawaii, Idaho, Montana, Oregon, Washington; 7 Illinois, Minnesota, North Dakota, South Dakota, Wisconsin; 8 Colorado, Iowa, Kansas, Missouri, Nebraska, Wyoming; 9 New York; 10 Indiana, Michigan, Ohio; 11 Kentucky, North Carolina, South Carolina, Tennessee, Virginia. Multivariate analyses adjust for all other covariates.